WebPureTech Health plc, a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, … WebGLYPHTM is part of ourEZ-SeamTMproduct group, which means there is no adhesive, seaming, sanding or filling of panel-to panel joints. Panel joints are simply caulked. …

University of Auckland: World first: researchers identify potential ...

WebSep 21, 2024 · The ground-breaking study, published in the prestigious journal Nature Metabolism, identified a profoundly damaging cycle in which a high fat diet promotes dysfunction of the mesenteric lymphatics, that in turn leads to accumulation of abdominal fat. WebDec 9, 2024 · LYT-300 is the first candidate from the GlyphTM technology platform to enter the clinic, making it the third clinical-stage candidate from PureTech’s pipeline. “Allopregnanolone is a powerful, natural regulator of mood disorders and other neurological conditions, but its therapeutic development has been limited by its poor oral bioavailability. primary aqd

Drug delivery technology enhances absorption of widely used …

WebAug 27, 2024 · PureTech is advancing its GlyphTM technology platform, which employs the body’s natural lipid absorption and transport process to orally administer drugs via the lymphatic system and bypass first-pass metabolism. PureTech has evaluated and validated more than 20 molecules as well as a range of novel linker chemistries with this … WebDec 18, 2024 · GlyphTM is specifically designed to enable the trafficking of small molecule drugs directly into the mesenteric lymphatic system following oral administration. The … WebGlyphTM is specifically designed to enable the trafficking of small molecule drugs directly into the mesenteric lymphatic system following oral administration. primary approved spouse pending 485